Terbutaline - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (3)Enzymes (1)

Targets (3)Enzymes (1)Biointeractions (4)

Identification

Name

Terbutaline

Accession Number

DB00871 (APRD00589)

Type

Small Molecule

Groups

Approved

Description

A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Terbutalin

Terbutalina

Terbutaline (sulfate de)

Terbutalini sulfas

Terbutalinsulfat

Terbutalinum

External IDs

KWD 2019

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Terbutaline Sulfate	576PU70Y8E	23031-32-5	MUPQZWGSBCWCAV-UHFFFAOYNA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Bricanyl Tab 2.5 mg	Tablet	2.5 mg	Oral	Astra Zeneca	1978-12-31	2000-07-20	Canada
Bricanyl Tab 5 mg	Tablet	5 mg	Oral	Astra Zeneca	1975-12-31	2001-07-23	Canada
Bricanyl Turbuhaler	Powder, metered	0.5 mg	Respiratory (inhalation)	Astra Zeneca	1990-12-31	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Terbutaline Sulfate	Tablet	5 mg/1	Oral	Av Kare, Inc.	2001-06-26	2015-12-29	US
Terbutaline Sulfate	Tablet	5 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2005-03-25	Not applicable	US
Terbutaline Sulfate	Tablet	2.5 mg/1	Oral	Red Pharm Drug, Inc.	2005-03-25	Not applicable	US
Terbutaline Sulfate	Injection	1 mg/mL	Subcutaneous	West Ward Pharmaceutical	2009-05-20	Not applicable	US
Terbutaline Sulfate	Injection	1 mg/mL	Subcutaneous	United Biomedical Inc., Asia	2014-12-15	Not applicable	US
Terbutaline Sulfate	Tablet	5 mg/1	Oral	Lannett Company, Inc.	2005-03-25	Not applicable	US
Terbutaline Sulfate	Tablet	2.5 mg/1	Oral	Av Kare, Inc.	2001-06-26	2015-12-29	US
Terbutaline Sulfate	Tablet	2.5 mg/1	Oral	Impax Generics	2001-06-26	Not applicable	US
Terbutaline Sulfate	Tablet	2.5 mg/1	Oral	Rebel Distributors	2005-03-25	Not applicable	US
Terbutaline Sulfate	Tablet	2.5 mg/1	Oral	Marlex Pharmaceuticals Inc	2014-10-01	Not applicable	US
Terbutaline Sulfate	Tablet	2.5 mg/1	Oral	Amerincan Health Packaging	2008-03-12	2016-01-01	US
Terbutaline Sulfate	Tablet	2.5 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Terbutaline Sulfate	Injection, solution	1 mg/mL	Subcutaneous	General Injectables & Vaccines	2011-11-16	Not applicable	US
Terbutaline Sulfate	Injection	1 mg/mL	Subcutaneous	Akorn	2010-02-01	Not applicable	US
Terbutaline Sulfate	Tablet	2.5 mg/1	Oral	Lannett Company, Inc.	2005-03-25	Not applicable	US
Terbutaline Sulfate	Tablet	5 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2001-06-26	Not applicable	US
Terbutaline Sulfate	Tablet	5 mg/1	Oral	Impax Generics	2001-06-26	Not applicable	US
Terbutaline Sulfate	Tablet	5 mg/1	Oral	Marlex Pharmaceuticals Inc	2014-10-01	Not applicable	US
Terbutaline Sulfate	Tablet	5 mg/1	Oral	Amerincan Health Packaging	2008-03-12	2016-01-01	US
Terbutaline Sulfate	Injection, solution	1 mg/mL	Subcutaneous	APP Pharmaceuticals, Inc.	2011-03-10	Not applicable	US
Terbutaline Sulfate	Tablet	5 mg/1	Oral	Rebel Distributors	2005-03-25	Not applicable	US
Terbutaline Sulfate	Injection, solution	1 mg/mL	Subcutaneous	Athenex Pharmaceutical Division, Llc.	2017-02-22	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Brethaire	Novartis
Brethine	Not Available
Bricanyl	AstraZeneca
Bricardyl	Johnson
Bricasma	AstraZeneca
Bricasol	AstraZeneca
Dracanyl	AstraZeneca
Terbasmin	AstraZeneca

Brand mixtures

Not Available

Categories

UNII

N8ONU3L3PG

CAS number

23031-25-6

Weight

Average: 225.2842
Monoisotopic: 225.136493479

Chemical Formula

C₁₂H₁₉NO₃

InChI Key

XWTYSIMOBUGWOL-UHFFFAOYSA-N

InChI

InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3

IUPAC Name

5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol

SMILES

CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1

Pharmacology

Indication

For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.

Structured Indications

Pharmacodynamics

Terbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation.

Mechanism of action

The pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Beta-2 adrenergic receptor	Protein	yes	agonist	Human	P07550	details
Beta-3 adrenergic receptor	Protein	unknown	agonist	Human	P13945	details
Beta-1 adrenergic receptor	Protein	unknown	antagonist	Human	P08588	details

Absorption

Approximately 30-50% if administered orally and well absorbed subcutaneously.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

About 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug. It appears that the sulfate conjugate is a major metabolite of terbutaline and urinary excretion is the primary route of elimination

Half life

5.5-5.9 hours

Clearance

311 +/- 112 mL/min

Toxicity

Terbutaline Sulfate: Oral LD₅₀(rat) = 8.7 g/kg; Oral LD₅₀(mouse) = 205 mg/kg; Oral LD₅₀(dog) = 1.5 g/kg; IP LD₅₀(rat)= 220 mg/kg ; IP LD₅₀(mouse) = 130 mg/kg; Oral LD₅₀(rabbit) = >8 g/kg; IV LD₅₀(mouse) = 36 mg/kg; IV LD₅₀(dog) = 116 mg/kg; IV LD₅₀(rabbit) = 110 mg/kg

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	The risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Terbutaline.	Experimental
Acebutolol	Acebutolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Alfuzosin	Alfuzosin may decrease the vasoconstricting activities of Terbutaline.	Approved, Investigational
Alprenolol	Alprenolol may decrease the bronchodilatory activities of Terbutaline.	Approved, Withdrawn
Amineptine	The risk or severity of adverse effects can be increased when Amineptine is combined with Terbutaline.	Illicit, Withdrawn
Amiodarone	Terbutaline may increase the QTc-prolonging activities of Amiodarone.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Amitriptyline is combined with Terbutaline.	Approved
Amphetamine	The risk or severity of adverse effects can be increased when Amphetamine is combined with Terbutaline.	Approved, Illicit
Anagrelide	Terbutaline may increase the QTc-prolonging activities of Anagrelide.	Approved
Arsenic trioxide	Terbutaline may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Terbutaline may increase the QTc-prolonging activities of Artemether.	Approved
Asenapine	Terbutaline may increase the QTc-prolonging activities of Asenapine.	Approved
Atenolol	Atenolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Atomoxetine	Atomoxetine may increase the hypertensive activities of Terbutaline.	Approved
Atosiban	The risk or severity of adverse effects can be increased when Terbutaline is combined with Atosiban.	Approved
Azithromycin	Terbutaline may increase the QTc-prolonging activities of Azithromycin.	Approved
Bedaquiline	Terbutaline may increase the QTc-prolonging activities of Bedaquiline.	Approved
Bendroflumethiazide	Terbutaline may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benmoxin	The risk or severity of adverse effects can be increased when Benmoxin is combined with Terbutaline.	Withdrawn
Benzphetamine	The risk or severity of adverse effects can be increased when Benzphetamine is combined with Terbutaline.	Approved, Illicit
Benzylpenicilloyl Polylysine	Terbutaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.	Approved
Betahistine	The therapeutic efficacy of Terbutaline can be decreased when used in combination with Betahistine.	Approved
Betaxolol	Betaxolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Bisoprolol	Bisoprolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Bopindolol	Bopindolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Bromocriptine	Bromocriptine may increase the hypertensive activities of Terbutaline.	Approved, Investigational
Bucindolol	The risk or severity of adverse effects can be increased when Terbutaline is combined with Bucindolol.	Investigational
Bumetanide	Terbutaline may increase the hypokalemic activities of Bumetanide.	Approved
Bupranolol	Bupranolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Cabergoline	Cabergoline may increase the hypertensive activities of Terbutaline.	Approved
Caroxazone	The risk or severity of adverse effects can be increased when Caroxazone is combined with Terbutaline.	Withdrawn
Carteolol	Carteolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Carvedilol	Carvedilol may decrease the vasoconstricting activities of Terbutaline.	Approved, Investigational
Celiprolol	Celiprolol may decrease the bronchodilatory activities of Terbutaline.	Approved, Investigational
Ceritinib	Terbutaline may increase the QTc-prolonging activities of Ceritinib.	Approved
Chloroquine	Terbutaline may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chlorothiazide	Terbutaline may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorphentermine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	Terbutaline may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Chlorthalidone	Terbutaline may increase the hypokalemic activities of Chlorthalidone.	Approved
Ciprofloxacin	Terbutaline may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	Terbutaline may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Citalopram	Terbutaline may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	Terbutaline may increase the QTc-prolonging activities of Clarithromycin.	Approved
Clenbuterol	The risk or severity of adverse effects can be increased when Terbutaline is combined with Clenbuterol.	Approved, Vet Approved
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Terbutaline.	Approved, Vet Approved
Clozapine	Terbutaline may increase the QTc-prolonging activities of Clozapine.	Approved
Crizotinib	Terbutaline may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Terbutaline.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline.	Approved
Desvenlafaxine	Desvenlafaxine may increase the tachycardic activities of Terbutaline.	Approved
Dihydroergotamine	Dihydroergotamine may increase the hypertensive activities of Terbutaline.	Approved
Disopyramide	Terbutaline may increase the QTc-prolonging activities of Disopyramide.	Approved
Dobutamine	The risk or severity of adverse effects can be increased when Dobutamine is combined with Terbutaline.	Approved
Dofetilide	Terbutaline may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Terbutaline may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	Terbutaline may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Dopamine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Dopamine.	Approved
Dosulepin	The risk or severity of adverse effects can be increased when Dosulepin is combined with Terbutaline.	Approved
Doxazosin	Doxazosin may decrease the vasoconstricting activities of Terbutaline.	Approved
Doxepin	The risk or severity of adverse effects can be increased when Doxepin is combined with Terbutaline.	Approved
Doxofylline	The risk or severity of adverse effects can be increased when Terbutaline is combined with Doxofylline.	Approved
Dronabinol	Dronabinol may increase the tachycardic activities of Terbutaline.	Approved, Illicit
Dronedarone	Terbutaline may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Terbutaline may increase the QTc-prolonging activities of Droperidol.	Approved, Vet Approved
Duloxetine	Duloxetine may increase the tachycardic activities of Terbutaline.	Approved
Eliglustat	Terbutaline may increase the QTc-prolonging activities of Eliglustat.	Approved
Ephedrine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Ephedrine.	Approved
Epinephrine	The risk or severity of adverse effects can be increased when Epinephrine is combined with Terbutaline.	Approved, Vet Approved
Ergoloid mesylate	Ergoloid mesylate may increase the hypertensive activities of Terbutaline.	Approved
Ergonovine	Ergonovine may increase the hypertensive activities of Terbutaline.	Approved
Ergotamine	Ergotamine may increase the hypertensive activities of Terbutaline.	Approved
Erythromycin	Terbutaline may increase the QTc-prolonging activities of Erythromycin.	Approved, Vet Approved
Escitalopram	Terbutaline may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Esmirtazapine	The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Terbutaline.	Investigational
Esmolol	Esmolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Etacrynic acid	Terbutaline may increase the hypokalemic activities of Etacrynic acid.	Approved
Etilefrine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Etilefrine.	Withdrawn
Fenoterol	The risk or severity of adverse effects can be increased when Terbutaline is combined with Fenoterol.	Approved
Flecainide	Terbutaline may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Fluoxetine	Terbutaline may increase the QTc-prolonging activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	Terbutaline may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Furazolidone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline.	Approved, Vet Approved
Furosemide	Terbutaline may increase the hypokalemic activities of Furosemide.	Approved, Vet Approved
Gadobenic acid	Terbutaline may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Gemifloxacin	Terbutaline may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Goserelin	Terbutaline may increase the QTc-prolonging activities of Goserelin.	Approved
Granisetron	Terbutaline may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Haloperidol	Terbutaline may increase the QTc-prolonging activities of Haloperidol.	Approved
Hydracarbazine	The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Terbutaline.	Experimental
Hydrochlorothiazide	Terbutaline may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	Terbutaline may increase the hypokalemic activities of Hydroflumethiazide.	Approved
Hydroxyamphetamine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Hydroxyamphetamine hydrobromide.	Approved
Ibutilide	Terbutaline may increase the QTc-prolonging activities of Ibutilide.	Approved
Iloperidone	Terbutaline may increase the QTc-prolonging activities of Iloperidone.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Terbutaline.	Approved
Indapamide	Terbutaline may increase the hypokalemic activities of Indapamide.	Approved
Indoramin	Indoramin may decrease the vasoconstricting activities of Terbutaline.	Withdrawn
Iobenguane	The therapeutic efficacy of Iobenguane can be decreased when used in combination with Terbutaline.	Approved
Iproclozide	The risk or severity of adverse effects can be increased when Iproclozide is combined with Terbutaline.	Withdrawn
Iproniazid	The risk or severity of adverse effects can be increased when Iproniazid is combined with Terbutaline.	Withdrawn
Isocarboxazid	The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terbutaline.	Approved
Isoprenaline	The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Isoxsuprine.	Approved, Withdrawn
Labetalol	The risk or severity of adverse effects can be increased when Labetalol is combined with Terbutaline.	Approved
Lenvatinib	Terbutaline may increase the QTc-prolonging activities of Lenvatinib.	Approved
Leuprolide	Terbutaline may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levofloxacin	Terbutaline may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomilnacipran	Levomilnacipran may increase the tachycardic activities of Terbutaline.	Approved
Linezolid	Linezolid may increase the hypertensive activities of Terbutaline.	Approved, Investigational
Lopinavir	Terbutaline may increase the QTc-prolonging activities of Lopinavir.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Loxapine.	Approved
Lumefantrine	Terbutaline may increase the QTc-prolonging activities of Lumefantrine.	Approved
Mebanazine	The risk or severity of adverse effects can be increased when Mebanazine is combined with Terbutaline.	Withdrawn
Mephentermine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Mephentermine.	Approved
Metaraminol	The risk or severity of adverse effects can be increased when Metaraminol is combined with Terbutaline.	Approved, Investigational
Methadone	Terbutaline may increase the QTc-prolonging activities of Methadone.	Approved
Methamphetamine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Methamphetamine.	Approved, Illicit
Methoxamine	The risk or severity of adverse effects can be increased when Methoxamine is combined with Terbutaline.	Approved
Methyclothiazide	Terbutaline may increase the hypokalemic activities of Methyclothiazide.	Approved
Methylene blue	The risk or severity of adverse effects can be increased when Methylene blue is combined with Terbutaline.	Investigational
Metolazone	Terbutaline may increase the hypokalemic activities of Metolazone.	Approved
Metoprolol	Metoprolol may decrease the bronchodilatory activities of Terbutaline.	Approved, Investigational
Midodrine	The risk or severity of adverse effects can be increased when Midodrine is combined with Terbutaline.	Approved
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Terbutaline.	Approved, Investigational
Milnacipran	Milnacipran may increase the tachycardic activities of Terbutaline.	Approved
Minaprine	The risk or severity of adverse effects can be increased when Minaprine is combined with Terbutaline.	Approved
Mirtazapine	The risk or severity of adverse effects can be increased when Mirtazapine is combined with Terbutaline.	Approved
Moclobemide	The risk or severity of adverse effects can be increased when Moclobemide is combined with Terbutaline.	Approved
Moxifloxacin	Terbutaline may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Nabilone	Nabilone may increase the tachycardic activities of Terbutaline.	Approved, Investigational
Nadolol	Nadolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Nebivolol	Nebivolol may decrease the bronchodilatory activities of Terbutaline.	Approved, Investigational
Nialamide	The risk or severity of adverse effects can be increased when Nialamide is combined with Terbutaline.	Withdrawn
Nilotinib	Terbutaline may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Norepinephrine	The risk or severity of adverse effects can be increased when Norepinephrine is combined with Terbutaline.	Approved
Nortriptyline	The risk or severity of adverse effects can be increased when Nortriptyline is combined with Terbutaline.	Approved
Nylidrin	The risk or severity of adverse effects can be increased when Terbutaline is combined with Nylidrin.	Approved
Octamoxin	The risk or severity of adverse effects can be increased when Octamoxin is combined with Terbutaline.	Withdrawn
Ofloxacin	Terbutaline may increase the QTc-prolonging activities of Ofloxacin.	Approved
Ondansetron	Terbutaline may increase the QTc-prolonging activities of Ondansetron.	Approved
Opipramol	The risk or severity of adverse effects can be increased when Opipramol is combined with Terbutaline.	Investigational
Orciprenaline	The risk or severity of adverse effects can be increased when Orciprenaline is combined with Terbutaline.	Approved
Oxprenolol	Oxprenolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Oxymetazoline	The risk or severity of adverse effects can be increased when Terbutaline is combined with Oxymetazoline.	Approved
Paliperidone	Terbutaline may increase the QTc-prolonging activities of Paliperidone.	Approved
Panobinostat	Terbutaline may increase the QTc-prolonging activities of Panobinostat.	Approved, Investigational
Pargyline	The risk or severity of adverse effects can be increased when Pargyline is combined with Terbutaline.	Approved
Pazopanib	Terbutaline may increase the QTc-prolonging activities of Pazopanib.	Approved
Penbutolol	Penbutolol may decrease the bronchodilatory activities of Terbutaline.	Approved, Investigational
Pentamidine	Terbutaline may increase the QTc-prolonging activities of Pentamidine.	Approved
Perflutren	Terbutaline may increase the QTc-prolonging activities of Perflutren.	Approved
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Terbutaline.	Approved
Pheniprazine	The risk or severity of adverse effects can be increased when Pheniprazine is combined with Terbutaline.	Withdrawn
Phenmetrazine	The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Terbutaline.	Approved, Illicit
Phenoxypropazine	The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Terbutaline.	Withdrawn
Phentermine	The risk or severity of adverse effects can be increased when Phentermine is combined with Terbutaline.	Approved, Illicit
Phenylephrine	The risk or severity of adverse effects can be increased when Phenylephrine is combined with Terbutaline.	Approved
Phenylpropanolamine	The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Terbutaline.	Approved, Vet Approved, Withdrawn
Pimozide	Terbutaline may increase the QTc-prolonging activities of Pimozide.	Approved
Pindolol	Pindolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Piretanide	Terbutaline may increase the hypokalemic activities of Piretanide.	Experimental
Pirlindole	The risk or severity of adverse effects can be increased when Pirlindole is combined with Terbutaline.	Approved
Pivhydrazine	The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Terbutaline.	Withdrawn
Polythiazide	Terbutaline may increase the hypokalemic activities of Polythiazide.	Approved
Prazosin	Prazosin may decrease the vasoconstricting activities of Terbutaline.	Approved
Primaquine	Terbutaline may increase the QTc-prolonging activities of Primaquine.	Approved
Procainamide	Terbutaline may increase the QTc-prolonging activities of Procainamide.	Approved
Procaterol	The risk or severity of adverse effects can be increased when Terbutaline is combined with Procaterol.	Approved
Promazine	Terbutaline may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Propafenone	Terbutaline may increase the QTc-prolonging activities of Propafenone.	Approved
Propranolol	Propranolol may decrease the bronchodilatory activities of Terbutaline.	Approved, Investigational
Protriptyline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline.	Approved
Pseudoephedrine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Pseudoephedrine.	Approved
Quetiapine	Terbutaline may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinethazone	Terbutaline may increase the hypokalemic activities of Quinethazone.	Approved
Quinidine	Terbutaline may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Terbutaline may increase the QTc-prolonging activities of Quinine.	Approved
Racepinephrine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Racepinephrine.	Approved
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Terbutaline.	Approved
Ritodrine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline.	Approved
Safrazine	The risk or severity of adverse effects can be increased when Safrazine is combined with Terbutaline.	Withdrawn
Saquinavir	Terbutaline may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Selegiline	The risk or severity of adverse effects can be increased when Selegiline is combined with Terbutaline.	Approved, Investigational, Vet Approved
Silodosin	Silodosin may decrease the vasoconstricting activities of Terbutaline.	Approved
Sotalol	Sotalol may decrease the bronchodilatory activities of Terbutaline.	Approved
Spironolactone	Spironolactone may decrease the vasoconstricting activities of Terbutaline.	Approved
Sulfisoxazole	Terbutaline may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Synephrine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Synephrine.	Experimental
Tamsulosin	Tamsulosin may decrease the vasoconstricting activities of Terbutaline.	Approved, Investigational
Tedizolid Phosphate	Tedizolid Phosphate may increase the hypertensive activities of Terbutaline.	Approved
Telavancin	Terbutaline may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	Terbutaline may increase the QTc-prolonging activities of Telithromycin.	Approved
Terazosin	Terazosin may decrease the vasoconstricting activities of Terbutaline.	Approved
Tetrabenazine	Terbutaline may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Tetryzoline	The risk or severity of adverse effects can be increased when Terbutaline is combined with Tetryzoline.	Approved
Thioridazine	Terbutaline may increase the QTc-prolonging activities of Thioridazine.	Withdrawn
Tianeptine	The risk or severity of adverse effects can be increased when Tianeptine is combined with Terbutaline.	Approved
Timolol	Timolol may decrease the bronchodilatory activities of Terbutaline.	Approved
Toloxatone	The risk or severity of adverse effects can be increased when Toloxatone is combined with Terbutaline.	Approved
Torasemide	Terbutaline may increase the hypokalemic activities of Torasemide.	Approved
Toremifene	Terbutaline may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Terbutaline.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.	Approved
Trichlormethiazide	Terbutaline may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Trimazosin	Trimazosin may decrease the vasoconstricting activities of Terbutaline.	Experimental
Trimipramine	The risk or severity of adverse effects can be increased when Trimipramine is combined with Terbutaline.	Approved
Tyramine	The risk or severity of adverse effects can be increased when Terbutaline is combined with Tyramine.	Investigational, Nutraceutical
Vandetanib	Terbutaline may increase the QTc-prolonging activities of Vandetanib.	Approved
Vemurafenib	Terbutaline may increase the QTc-prolonging activities of Vemurafenib.	Approved
Venlafaxine	Venlafaxine may increase the tachycardic activities of Terbutaline.	Approved
Ziprasidone	Terbutaline may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zuclopenthixol	Terbutaline may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Alison B. Lukacsko, Joseph J. Piala, "Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions." U.S. Patent US5260333, issued December, 1983.

US5260333

General References

Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, Slotkin TA: Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10. [PubMed:14610225 ]
Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [PubMed:1358833 ]
Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [PubMed:2062329 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15009
KEGG Compound	C07129
PubChem Compound	5403
PubChem Substance	46506887
ChemSpider	5210
BindingDB	25770
ChEBI	9449
ChEMBL	CHEMBL1760
Therapeutic Targets Database	DAP000246
PharmGKB	PA451616
IUPHAR	560
Guide to Pharmacology	560
Drug Product Database	2345
RxList	http://www.rxlist.com/cgi/generic3/terbutaline.htm
Drugs.com	http://www.drugs.com/cdi/terbutaline.html
Wikipedia	Terbutaline

ATC Codes

R03CC53 — Terbutaline, combinations

R03AC03 — Terbutaline

R03CC03 — Terbutaline

AHFS Codes

12:12.08.12

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (73.1 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Prevention	Diabetes, Diabetes Mellitus Type 1	1
2	Completed	Treatment	Exercised Induced Asthma	1
2, 3	Terminated	Treatment	External Cephalic Version	1
3	Completed	Treatment	Asthma Bronchial	3
3	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	1
3	Recruiting	Treatment	Acute Exacerbation of Chronic Obstructive Airways Disease / Chronic Obstructive Pulmonary Disease Exacerbation	1
4	Completed	Treatment	Asthma Bronchial	1
4	Completed	Treatment	Heart Failure, Unspecified	1
4	Completed	Treatment	Status Asthmaticus	1
4	Recruiting	Treatment	External Cephalic Version	1
4	Unknown Status	Not Available	Asthma Bronchial	1
4	Unknown Status	Treatment	Labour Pain	1
Not Available	Completed	Basic Science	Skeletal Muscle Fatigue in Humans	1
Not Available	Completed	Treatment	Diabetes, Diabetes Mellitus Type 1	1
Not Available	Completed	Treatment	Foetal distress syndrome	1
Not Available	Completed	Treatment	Reproductive Techniques, Assisted	1
Not Available	Recruiting	Basic Science	Muscle Hypertrophy in Healthy Young Men	1

Pharmacoeconomics

Manufacturers

Novartis pharmaceuticals corp
Sanofi aventis us llc
Aaipharma llc
Akorn inc
App pharmaceuticals llc
Bedford laboratories div ben venue laboratories inc
Hikma farmaceutica (portugal) sa
Teva parenteral medicines inc
Impax laboratories inc
Lannett holdings inc

Packagers

Akorn Inc.
Amerisource Health Services Corp.
APP Pharmaceuticals
AstraZeneca Inc.
Bedford Labs
Ben Venue Laboratories Inc.
Cardinal Health
Dept Health Central Pharmacy
Dispensing Solutions
Gallipot
Global Pharmaceuticals
Hikma Pharmaceuticals
Lannett Co. Inc.
Mckesson Corp.
Murfreesboro Pharmaceutical Nursing Supply
Novartis AG
Nucare Pharmaceuticals Inc.
Pharmaceutical Utilization Management Program VA Inc.
Physicians Total Care Inc.
Rebel Distributors Corp.
Redpharm Drug
Remedy Repack
Resource Optimization and Innovation LLC
Rite Aid Corp.
Teva Pharmaceutical Industries Ltd.
Tya Pharmaceuticals
West-Ward Pharmaceuticals

Dosage forms

Form	Route	Strength
Tablet	Oral	2.5 mg
Tablet	Oral	5 mg
Powder, metered	Respiratory (inhalation)	0.5 mg
Injection	Subcutaneous	1 mg/mL
Injection, solution	Subcutaneous	1 mg/mL
Tablet	Oral	2.5 mg/1
Tablet	Oral	5 mg/1

Prices

Unit description	Cost	Unit
Terbutaline sulfate powder	38.4USD	g
Terbutaline Sulfate 1 mg/ml vial	12.99USD	vial
Terbutaline sulf 1 mg/ml vial	4.8USD	ml
Brethine 5 mg tablet	0.83USD	tablet
Terbutaline sulfate 5 mg tablet	0.63USD	tablet
Brethine 2.5 mg tablet	0.57USD	tablet
Terbutaline sulfate 2.5 mg tablet	0.47USD	tablet
Bricanyl Turbuhaler 0.5 mg/dose Metered Inhalation Powder	0.08USD	dose

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	119-122 °C	Not Available
water solubility	213 mg/mL	Not Available
logP	0.90	TACAKS-NOVAK,K ET AL. (1995)
Caco2 permeability	-6.38	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	5.84 mg/mL	ALOGPS
logP	0.55	ALOGPS
logP	0.44	ChemAxon
logS	-1.6	ALOGPS
pKa (Strongest Acidic)	8.86	ChemAxon
pKa (Strongest Basic)	9.76	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	72.72 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	63.04 m³·mol^-1	ChemAxon
Polarizability	24.78 Å³	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.987
Blood Brain Barrier	-	0.9355
Caco-2 permeable	-	0.8404
P-glycoprotein substrate	Substrate	0.6335
P-glycoprotein inhibitor I	Non-inhibitor	0.8954
P-glycoprotein inhibitor II	Non-inhibitor	0.9672
Renal organic cation transporter	Non-inhibitor	0.9067
CYP450 2C9 substrate	Non-substrate	0.7678
CYP450 2D6 substrate	Non-substrate	0.7922
CYP450 3A4 substrate	Non-substrate	0.6291
CYP450 1A2 substrate	Non-inhibitor	0.9516
CYP450 2C9 inhibitor	Non-inhibitor	0.9303
CYP450 2D6 inhibitor	Non-inhibitor	0.923
CYP450 2C19 inhibitor	Non-inhibitor	0.9115
CYP450 3A4 inhibitor	Non-inhibitor	0.8766
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9117
Ames test	Non AMES toxic	0.9119
Carcinogenicity	Non-carcinogens	0.8484
Biodegradation	Not ready biodegradable	0.9808
Rat acute toxicity	2.1080 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9548
hERG inhibition (predictor II)	Non-inhibitor	0.9467

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-004i-0290000000-8c26dbc913131cf49bc4	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0udi-0900000000-3148282c5452a80b16c3	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0udi-0900000000-9122151a6e70e6f2b536	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-004i-0090000000-aab7f309385309d8884b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-0udi-0920000000-1e85cd2bf4a0358c22d7	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-0udi-0900000000-82b70479a4e38921e06b	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-0a4i-2900000000-aff994ffd107ef3b6e71	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-0a6r-7900000000-cfe77aa0133facea1c75	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-IT , positive	splash10-0udi-0900000000-1a0ccd393797b19105a0	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-004i-0190000000-f9271bb736a512dbdbab	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0udi-0900000000-a70c8697ca7633839444	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a6r-1900000000-4a9c0ddb9af4ce93b4ae	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0a6r-6900000000-0cc68c4a50196d6ffab6	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-004i-9400000000-e1cec349ffb2fcd3ebe2	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as resorcinols. These are compounds containing a resorcinol moiety, which is a benzene ring bearing two hydroxyl groups at positions 1 and 3.

Kingdom

Super Class

Class

Sub Class

Direct Parent

Alternative Parents

Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols

Substituents

Resorcinol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Monocyclic benzene moiety / 1,2-aminoalcohol / Secondary alcohol / Secondary amine / Secondary aliphatic amine / Aromatic alcohol

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

phenylethanolamines, resorcinols (CHEBI:9449 )

Targets

Details

1. Beta-2 adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Protein homodimerization activity
Specific Function:: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:: ADRB2
Uniprot ID:: P07550
Uniprot Name:: Beta-2 adrenergic receptor
Molecular Weight:: 46458.32 Da

References

Schafers RF, Piest U, von Birgelen C, Jakubetz J, Daul AE, Philipp T, Brodde OE: Disodium cromoglycate does not prevent terbutaline-induced desensitization of beta 2-adrenoceptor-mediated cardiovascular in vivo functions in human volunteers. J Cardiovasc Pharmacol. 1999 May;33(5):822-7. [PubMed:10226872 ]
Ramer-Quinn DS, Swanson MA, Lee WT, Sanders VM: Cytokine production by naive and primary effector CD4+ T cells exposed to norepinephrine. Brain Behav Immun. 2000 Dec;14(4):239-55. [PubMed:11120594 ]
Zetterlund A, Hjemdahl P, Larsson K: beta2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide. Clin Sci (Lond). 2001 Apr;100(4):451-7. [PubMed:11256987 ]
Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T: Activation of beta(2)-adrenoceptor prevents shiga toxin 2-induced TNF-alpha gene transcription. J Am Soc Nephrol. 2001 Nov;12(11):2288-99. [PubMed:11675405 ]
Chong LK, Suvarna K, Chess-Williams R, Peachell PT: Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. Br J Pharmacol. 2003 Feb;138(3):512-20. [PubMed:12569076 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Riether C, Kavelaars A, Wirth T, Pacheco-Lopez G, Doenlen R, Willemen H, Heijnen CJ, Schedlowski M, Engler H: Stimulation of beta(2)-adrenergic receptors inhibits calcineurin activity in CD4(+) T cells via PKA-AKAP interaction. Brain Behav Immun. 2011 Jan;25(1):59-66. doi: 10.1016/j.bbi.2010.07.248. Epub 2010 Jul 30. [PubMed:20674738 ]
Cooperberg BA, Breckenridge SM, Arbelaez AM, Cryer PE: Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2008 Dec;31(12):2271-2. doi: 10.2337/dc08-0520. Epub 2008 Sep 9. [PubMed:18782903 ]
Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [PubMed:1358833 ]
Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [PubMed:2062329 ]

Details

2. Beta-3 adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: agonist

General Function:: Protein homodimerization activity
Specific Function:: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:: ADRB3
Uniprot ID:: P13945
Uniprot Name:: Beta-3 adrenergic receptor
Molecular Weight:: 43518.615 Da

References

Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417 ]
Behr B, Hoffmann C, Ottolina G, Klotz KN: Novel mutants of the human beta1-adrenergic receptor reveal amino acids relevant for receptor activation. J Biol Chem. 2006 Jun 30;281(26):18120-5. Epub 2006 Apr 28. [PubMed:16648137 ]

Details

3. Beta-1 adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Receptor signaling protein activity
Specific Function:: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:: ADRB1
Uniprot ID:: P08588
Uniprot Name:: Beta-1 adrenergic receptor
Molecular Weight:: 51322.1 Da

References

Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417 ]

Enzymes

Details

1. Cholinesterase

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Identical protein binding
Specific Function:: Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:: BCHE
Uniprot ID:: P06276
Uniprot Name:: Cholinesterase
Molecular Weight:: 68417.575 Da

References

Kovarik Z, Simeon-Rudolf V: Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline. J Enzyme Inhib Med Chem. 2004 Apr;19(2):113-7. [PubMed:15449725 ]

Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:33

Structure for DB00871 (Terbutaline)

Targets

References

References

References

Enzymes

References